Cellular transport of CI-980 Kenneth E. HookSally A. PrzybranowskiW. R. Leopold Preclinical Studies Pages: 341 - 347
Preclinical antitumor activity of CI-994 Patricia Mucci LoRussoLisa DemchikThomas H. Corbett Preclinical Studies Pages: 349 - 356
Effects of 13-hydroxy SM5887 in combination with other anticancer agents on human tumor cell lines Tatsuya TakagiYasuo YazawaYasuhiko Kano Preclinical Studies Pages: 357 - 363
Murraya koenigii and Brassica juncea — Alterations on lipid profile in 1–2 dimethyl hydrazine induced colon carcinogenesis Beena A. KhanAnnie AbrahamS. Leelamma Preclinical Studies Pages: 365 - 369
Clinical phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patients Tassilo SchillingHeiner H. FiebigAxel-R Hanauske Phase I Studies Pages: 371 - 378
Clinical and pharmacokinetic phase I trial of oral dimethylaminoetoposide (NK611) administered for 21 days every 35 days I. RaßmannH. SchrödelA. -R. Hanauske Phase I Studies Pages: 379 - 386
Phase I trial of recombinant platelet factor 4 (rPF4) in patients with advanced colorectal carcinoma Neil BelmanEric M. BonnemAllan Lipton Phase I Studies Pages: 387 - 389
13-Cis-retinoic acid and interferon alpha-2a in patients with advanced esophageal cancer: A phase II trial Coenraad F. SlabberGeoffrey FalksonLizette Schoeman Phase II Studies Pages: 391 - 394
A phase II trial of a differentiating agent (tRA) with cisplatin-VP 16 chemotherapy in advanced non-small cell lung cancer Raghu ThiruvengadamJoshua O. AtibaSamar H. Azawi Phase II Studies Pages: 395 - 401
Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck Roy E. SmithDanika LewJohn F. Ensley Phase II Studies Pages: 403 - 407
A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer Robert S. WittePeggy HsiehDonald L. Trump Phase II Studies Pages: 409 - 413
Phase II study of mitonafide in non-small cell lung cancer (NSCLC) Antonio CasadoRafael RosellMiguel Martín Phase II Studies Pages: 415 - 417
Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-Fluorouracil in advanced gastric adenocarcinoma Roy L. MartinoThomas R. FlemingJohn S. Macdonald Phase II Studies Pages: 419 - 421